Sopharma Goes To Ukraine

596
The management of Sopharma ()  has approved a decision to acquire a company in Ukraine. The Board of Directors authorized CEO Ognyan Donev to lead negotiations, and take all necessary steps to seal the deal for the acquisition of a Ukrainian company.

As was announced in early October, Sopahrama subscribed 108,500 shares from the capital of Latvian Olinepharma in the company's IPO.

And at the end of September Sopharma signed a contract with Polish Natur Product Zdrovit for the setting up of a joint company.

It became clear last month that Sopharma has made its first product registration on the Turkish market.

Metilprednizolon is an anti-inflammatory and anti-allergic medication that is widely used in urgent care and in cases of serious shocks or in chronic conditions, which are not affected by standard medications.

The stock dropped 1.8% to an average of 8.72 leva at a turnover f 15,744 shares.

Facebook Коментари

Добави коментар

Екипът на Profit.bg Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на Profit.bg